L Lauerová

506 total citations
31 papers, 416 citations indexed

About

L Lauerová is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, L Lauerová has authored 31 papers receiving a total of 416 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Immunology and 9 papers in Molecular Biology. Recurrent topics in L Lauerová's work include Immunotherapy and Immune Responses (10 papers), Cytokine Signaling Pathways and Interactions (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). L Lauerová is often cited by papers focused on Immunotherapy and Immune Responses (10 papers), Cytokine Signaling Pathways and Interactions (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). L Lauerová collaborates with scholars based in Czechia, Russia and Netherlands. L Lauerová's co-authors include Jan Kovařík, Ivo Kocák, Bořivoj Vojtěšek, Ladislav Dušek, Jan Žaloudík, Miloslava Fojtová, Hana Doležalová, David P. Lane, Aleš Rejthar and Jiří Bártek and has published in prestigious journals such as British Journal of Cancer, International Journal of Cancer and European Journal of Cancer.

In The Last Decade

L Lauerová

28 papers receiving 399 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L Lauerová Czechia 11 231 173 159 41 40 31 416
Christopher Taylor United States 3 179 0.8× 206 1.2× 156 1.0× 23 0.6× 41 1.0× 6 494
Goki Gon Japan 3 251 1.1× 188 1.1× 263 1.7× 30 0.7× 32 0.8× 3 518
P Hageman Netherlands 6 212 0.9× 82 0.5× 183 1.2× 80 2.0× 33 0.8× 6 454
Marina Castellano Australia 7 165 0.7× 154 0.9× 198 1.2× 47 1.1× 12 0.3× 7 399
Desmond Roche Ireland 6 222 1.0× 280 1.6× 340 2.1× 15 0.4× 22 0.6× 8 537
Naoshi Kawamura Japan 10 233 1.0× 204 1.2× 156 1.0× 29 0.7× 13 0.3× 12 456
Jennifer Smith United States 8 362 1.6× 137 0.8× 132 0.8× 67 1.6× 29 0.7× 11 570
Phillip H. Koeffler United States 6 205 0.9× 50 0.3× 336 2.1× 62 1.5× 45 1.1× 13 467
Jane Ann Smith Canada 4 212 0.9× 60 0.3× 147 0.9× 78 1.9× 32 0.8× 4 380
Roshini M. Ponnamperuma United States 9 233 1.0× 99 0.6× 331 2.1× 28 0.7× 45 1.1× 13 489

Countries citing papers authored by L Lauerová

Since Specialization
Citations

This map shows the geographic impact of L Lauerová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Lauerová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Lauerová more than expected).

Fields of papers citing papers by L Lauerová

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L Lauerová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Lauerová. The network helps show where L Lauerová may publish in the future.

Co-authorship network of co-authors of L Lauerová

This figure shows the co-authorship network connecting the top 25 collaborators of L Lauerová. A scholar is included among the top collaborators of L Lauerová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L Lauerová. L Lauerová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kovařík, Jan, et al.. (2009). Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein. European Journal of Cancer. 45(7). 1315–1323. 11 indexed citations
2.
Součková, Kamila, Ladislav Dušek, L Lauerová, et al.. (2009). Reduced inducibility of SOCS3 by interferon gamma associates with higher resistance of human breast cancer lines as compared to normal mammary epithelial cells. Neoplasma. 56(5). 379–386. 3 indexed citations
3.
Slabý, Ondřej, et al.. (2009). Expression pattern of HLA class I antigens in renal cell carcinoma and primary cell line cultures: methodological implications for immunotherapy.. PubMed. 15(12). CR638–43. 20 indexed citations
4.
Fojtová, Miloslava, et al.. (2007). Development of IFN-γ resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells. British Journal of Cancer. 97(2). 231–237. 33 indexed citations
5.
Kovařı́k, Aleš, et al.. (2005). Interferon-??, but not interferon-??, induces SOCS 3 expression in human melanoma cell lines. Melanoma Research. 15(6). 481–488. 18 indexed citations
6.
Kocák, Ivo, et al.. (2003). Interferon Inducibility of STAT 1 Activation and Its Prognostic Significance in Melanoma Patients. Folia Biologica. 49(4). 142–146. 10 indexed citations
7.
Lauerová, L, et al.. (2002). Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response.. PubMed. 49(3). 159–66. 80 indexed citations
8.
Žaloudík, Jan, et al.. (1999). Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver.. PubMed. 46(25). 220–7. 19 indexed citations
9.
Lauerová, L, Ladislav Dušek, Pavel Šlampa, et al.. (1999). Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.. PubMed. 46(3). 141–9. 8 indexed citations
10.
Vojtěšek, Bořivoj, Jan Kovařík, Rudolf Nenutil, et al.. (1995). p53 protein overexpression associates with growth patterns rather than with metastasizing in operable breast cancer.. PubMed. 42(6). 331–6.
11.
Vojtěšek, Bořivoj, Hana Doležalová, L Lauerová, et al.. (1995). Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein.. PubMed. 10(2). 389–93. 67 indexed citations
12.
Smedts, Frank, Frans C. S. Ramaekers, M Link, et al.. (1994). Detection of keratin subtypes in routinely processed cervical tissue: implications for tumour classification and the study of cervix cancer aetiology. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 425(2). 145–55. 22 indexed citations
13.
Lauerová, L, et al.. (1992). Fusion-induced malignancy? A preliminary study. (a challenge to today's common wisdom).. PubMed. 39(2). 79–86. 8 indexed citations
14.
Kovařík, Jan, J Bártek, A Rejthar, Jiřina Bártková, & L Lauerová. (1985). Development, characterization and clinical applications of a new anti-keratin monoclonal antibody. European Journal of Cancer and Clinical Oncology. 21(11). 1396–1396. 3 indexed citations
15.
Bártek, Jiří, et al.. (1985). Monoclonal antibody to intermediate filaments of cytokeratin type. I. Drug studies and reactivity with cultured cells and tissue sections.. PubMed. 31(1). 1–8. 2 indexed citations
16.
Kovařík, Jan, et al.. (1983). Leukocyte adherence inhibition responses obtained with various tumor extracts in breast cancer patients.. PubMed. 6(1-2). 215–9.
17.
Kovařík, Josef, et al.. (1983). DNCB and PPD skin testing in breast cancer.. PubMed. 30(4). 385–9. 1 indexed citations
18.
Lauerová, L, et al.. (1980). Humoral and cellular immunity in long-term surviving patients with malignant lymphoma.. PubMed. 27(3). 301–6. 4 indexed citations
19.
Kovařík, Jan, et al.. (1979). Evaluation of three E-rosette assays in melanoma patients. Cancer Immunology Immunotherapy. 6(2). 121–124. 2 indexed citations
20.
Kovařík, Jan, et al.. (1978). Establishment of cell line derived from human malignant melanoma.. PubMed. 25(6). 701–12. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026